home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407f.zip
/
M9471090.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
2KB
|
33 lines
Document 1090
DOCN M9471090
TI Novel combination chemotherapy for HIV-related non-Hodgkin's lymphoma
(HIV-NHL) (Meeting abstract).
DT 9409
AU Sawka C; Shepherd F; Brandwein J; Berinstein N; Singer J; Canadian HIV
Trials Network, Vancouver, Canada
SO Proc Annu Meet Am Soc Clin Oncol; 13:A13 1994. Unique Identifier :
AIDSLINE ICDB/94600010
AB Conventional-dose chemotherapy is poorly tolerated in HIV-NHL; even
low-dose programs including our half-dose weekly drug program (Leukemia
and Lymphoma 1992, 8:213-220) have been associated with significant
febrile neutropenia rates. We designed a novel chemotherapy program to
attempt to reduce this complication while maintaining efficacy. The
program consisted of six 21 day cycles of: etoposide 50 mg po od d1-14,
vincristine 2 mg iv d1, prednisone 100 mg po d 1-4, ara-c 50 mg IT d1.
Mitoxantrone 6 mg/m2 was given iv d1 on cycles 1,3,5; cyclophosphamide
300 mg/m2 was given iv d1 on cycles 2,4,6. Septra or aerosol pentamidine
was given throughout treatment and anti-retrovirals were started at
DE Adult Antineoplastic Agents, Combined/ADVERSE EFFECTS/*THERAPEUTIC USE
Cyclophosphamide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
Cytarabine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Dose-Response
Relationship, Drug Drug Administration Schedule
Etoposide/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Human Lymphoma,
AIDS-Related/*DRUG THERAPY/MORTALITY Male Mitoxantrone/ADMINISTRATION
& DOSAGE/ADVERSE EFFECTS Prednisone/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS Survival Rate Vincristine/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).